MSC Based Therapies-New Perspectives for the Injured Lung

Chronic lung diseases pose a tremendous global burden. At least one in four people suffer from severe pulmonary sequelae over the course of a lifetime. Despite substantial improvements in therapeutic interventions, persistent alleviation of clinical symptoms cannot be offered to most patients affect...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2020-03, Vol.9 (3), p.682
Main Authors: Behnke, Judith, Kremer, Sarah, Shahzad, Tayyab, Chao, Cho-Ming, Böttcher-Friebertshäuser, Eva, Morty, Rory E, Bellusci, Saverio, Ehrhardt, Harald
Format: Article
Language:English
Subjects:
Antimicrobial agents
Asthma
Bone marrow
Chronic illnesses
Chronic obstructive pulmonary disease
Clinical medicine
Cytokines
Disease prevention
Genotype & phenotype
Growth factors
Inflammation
Lung diseases
MicroRNAs
Nitric oxide
Pulmonary fibrosis
Review
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic lung diseases pose a tremendous global burden. At least one in four people suffer from severe pulmonary sequelae over the course of a lifetime. Despite substantial improvements in therapeutic interventions, persistent alleviation of clinical symptoms cannot be offered to most patients affected to date. Despite broad discrepancies in origins and pathomechanisms, the important disease entities all have in common the pulmonary inflammatory response which is central to lung injury and structural abnormalities. Mesenchymal stem cells (MSC) attract particular attention due to their broadly acting anti-inflammatory and regenerative properties. Plenty of preclinical studies provided congruent and convincing evidence that MSC have the therapeutic potential to alleviate lung injuries across ages. These include the disease entities bronchopulmonary dysplasia, asthma and the different forms of acute lung injury and chronic pulmonary diseases in adulthood. While clinical trials are so far restricted to pioneering trials on safety and feasibility, preclinical results point out possibilities to boost the therapeutic efficacy of MSC application and to take advantage of the MSC secretome. The presented review summarizes the most recent advances and highlights joint mechanisms of MSC action across disease entities which provide the basis to timely tackle this global disease burden.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm9030682